Drug Delivery to Skin by Needle-Free Injector

  • Hiroaki TodoEmail author


The transdermal drug delivery system (TDDS) has several advantages including the avoidance of the hepatic first-pass effect of drugs, long-acting sustained release of drugs, improved patient compliance, and painless administration. However, traditional TDDS has a limitation for the molecular size of drugs (<500 Da). Thus, TDDS formulations are not suitable for administration of high molecular hydrophilic drugs, such as proteins and vaccines. To overcome this problem, physicochemical methods, such as electroporation, microneedle, and needle-free injection (NFI), are becoming popular to increase skin permeation of mal-absorptive drugs. Among these techniques, NFIs have been investigated as an administration device not only for high molecular weight compounds like insulin and human-growth hormone, but also for vaccine and gene delivery. Currently biotechnology-derived medications are the leading edge of medical treatment and many biopharmaceuticals have dominated the top 10 used agents in the global market. In the near feature, development of self-administered injectable biopharmaceuticals associated with NFI or a combination of NFI and new transdermal drug innovative technologies will be needed to be able to incorporate and used into normal routines within patients’ homes and work places.


Needle-free injection Transdermal drug delivery Systemic drug delivery Local drug delivery High molecular weight compounds 


  1. 1.
    Imoto J-I, Konishi E (2005) Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol 18:205–212CrossRefPubMedGoogle Scholar
  2. 2.
    Jackson LA, Austin G, Chen RT et al (2001) Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19:4703–4709CrossRefPubMedGoogle Scholar
  3. 3.
    Agerso H, Moller-Pedersen J, Cappi S et al (2002) Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. J Clin Pharmacol 42:1262–1268CrossRefPubMedGoogle Scholar
  4. 4.
    Jovanovic-Peterson L, Palmer JP, Sparks S, Peterson CM (1993) Jet-injected insulin is associated with decreased antibody production and postprandial glucose variability when compared with needle-injected insulin in gestational diabetic women. Diabetes Care 16:1479–1484CrossRefPubMedGoogle Scholar
  5. 5.
    Theintz GE, Sizonenko PC (1991) Risks of jet injection of insulin in children. Eur J Pediatr 150:554–556CrossRefPubMedGoogle Scholar
  6. 6.
    Inoue N, Kobayashi D, Kimura M et al (1996) Fundamental investigation of a novel drug delivery system, a transdermal delivery system with jet injection. Int J Pharm 137:75–84CrossRefGoogle Scholar
  7. 7.
    Schramm-Baxter J, Mitragotri S (2004) Needle-free jet injections: dependence of jet penetration and dispersion in the skin on jet power. J Control Release 97:527–535CrossRefPubMedGoogle Scholar
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
    Arora A, Hakim I, Baxter J et al (2007) Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc Natl Acad Sci U S A 104:4255–4260CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Stachowiak JC, Li TH, Arora A et al (2009) Dynamic control of needle-free jet injection. J Control Release 135:104–112CrossRefPubMedGoogle Scholar
  20. 20.
    Stachowiak JC, von Muhlen MG, Li TH et al (2007) Piezoelectric control of needle-free transdermal drug delivery. J Control Release 124:88–97CrossRefPubMedGoogle Scholar
  21. 21.
    Bos JD, Meinardi MMHM (2000) The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9:1–5CrossRefGoogle Scholar
  22. 22.
    Prausnitz MR (2004) Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581–587CrossRefPubMedGoogle Scholar
  23. 23.
    Tokudome Y, Sugibayashi K (2004) Mechanism of the synergic effects of calcium chloride and electroporation on the in vitro enhanced skin permeation of drugs. J Control Release 95:267–274CrossRefPubMedGoogle Scholar
  24. 24.
    Baxter J, Mitragotri S (2005) Jet-induced skin puncture and its impact on needle-free jet injections: experimental studies and a predictive model. J Control Release 106:361–373CrossRefPubMedGoogle Scholar
  25. 25.
    Schramm J, Mitragotri S (2002) Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. Pharm Res 19:1673–1679CrossRefPubMedGoogle Scholar
  26. 26.
    Yoshida D, Todo H, Hasegawa T, Sugibayashi K (2008) Effect of molecular weight on the dermatopharmacokinetics and systemic disposition of drugs after intracutaneous injection. Eur J Pharm Sci 35:5–11CrossRefPubMedGoogle Scholar
  27. 27.
    Yoshida D, Todo H, Hasegawa T, Sugibayashi K (2008) Effect of vasoactive agents on the dermatopharmacokinetics and systemic disposition of model compounds, salicylate and FITC-dextran 4 kDa, following intracutaneous injection of the compounds. Int J Pharm 356:181–186CrossRefPubMedGoogle Scholar
  28. 28.
    Ritger PL, Peppas NA (1987) A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 5:23–36CrossRefGoogle Scholar
  29. 29.
    Higuchi WI (1962) Analysis of data on the medicament release from ointments. J Pharm Sci 51:802–804CrossRefPubMedGoogle Scholar
  30. 30.
    Yoshida D, Todo H, Hasegawa T, Sugibayashi K (2007) Dermatopharmacokinetics of salicylate following topical injection in rats: effect of osmotic pressure and injection volume on salicylate disposition. Int J Pharm 337:142–147Google Scholar
  31. 31.
    Anderson DM, Shelley S, Crick N, Buraglio M (2002) No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 42:1358–1365CrossRefPubMedGoogle Scholar
  32. 32.
    Simon JK, Carter M, Pasetti MF et al (2011) Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Vaccine 29:9544–9550CrossRefPubMedGoogle Scholar
  33. 33.
    McAllister L, Anderson J, Werth K et al (2014) Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 384:674–681CrossRefPubMedGoogle Scholar
  34. 34.
    Grosenbaugh DA, Leard T, Pardo MC et al (2004) Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. Vet Ther 5:258–262PubMedGoogle Scholar
  35. 35.
    Jones GF, Rapp-Gabrielson V, Wilke R et al (2005) Intradermal vaccination for mycoplasma hyopneumoniae. J Swine Health Prod 13:19–27Google Scholar
  36. 36.
    Williams J, Fox-Leyva L, Christensen C et al (2000) Hepatitis a vaccine administration: comparison between jet-injector and needle injection. Vaccine 18:1939–1943CrossRefPubMedGoogle Scholar
  37. 37.
    Pehling GB, Gerich JE (1984) Comparison of plasma insulin profiles after subcutaneous administration of insulin by jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clin Proc 59:751–754CrossRefPubMedGoogle Scholar
  38. 38.
    Kerum G, Profozić V, Granić M et al (1987) Blood glucose and free insulin levels after the administration of insulin by conventional syringe or jet injector in insulin treated type 2 diabetics. Horm Metab Res 19:422–425CrossRefPubMedGoogle Scholar
  39. 39.
    Verhagen A, Ebels JT, Jonkman JHG, Dogterom AA (1995) Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection. Eur J Clin Pharmacol 49:69–72CrossRefPubMedGoogle Scholar
  40. 40.
    Brearley C, Priestley A, Leighton-Scott J, Christen M (2007) Pharmacokinetics of recombinant human growth hormone administered by cool.Click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle. BMC Clin Pharmacol 7:1–7CrossRefGoogle Scholar
  41. 41.
    Engwerda EEC, Abbink EJ, Tack CJ, De Galan BE (2011) Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 34:1804–1808CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Walter JR, Xu S (2015) Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook. Drug Discov Today 20:1293–1299CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  1. 1.Faculty of Pharmacy and Pharmaceutical SciencesJosai UniversitySakadoJapan

Personalised recommendations